Free Trial

Evercore ISI Has Lowered Expectations for Hologic (NASDAQ:HOLX) Stock Price

Hologic logo with Medical background

Hologic (NASDAQ:HOLX - Free Report) had its target price trimmed by Evercore ISI from $65.00 to $62.00 in a report released on Friday morning,Benzinga reports. The firm currently has an in-line rating on the medical equipment provider's stock.

A number of other analysts also recently commented on the stock. Royal Bank of Canada decreased their price objective on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a report on Thursday, February 6th. Stephens restated an "overweight" rating and set a $84.00 target price on shares of Hologic in a report on Thursday, February 6th. Raymond James reiterated an "outperform" rating and set a $90.00 target price (down from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Morgan Stanley dropped their price target on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Finally, Needham & Company LLC restated a "hold" rating on shares of Hologic in a report on Friday, May 2nd. Twelve equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $79.85.

View Our Latest Research Report on HOLX

Hologic Price Performance

NASDAQ:HOLX traded up $1.98 during trading hours on Friday, reaching $55.09. 6,761,187 shares of the company were exchanged, compared to its average volume of 2,044,193. The stock's 50-day moving average is $59.85 and its 200-day moving average is $68.78. Hologic has a twelve month low of $51.90 and a twelve month high of $84.67. The firm has a market cap of $12.36 billion, a PE ratio of 17.33, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same period in the previous year, the business posted $1.03 EPS. Hologic's revenue was down 1.2% on a year-over-year basis. On average, sell-side analysts anticipate that Hologic will post 4.28 earnings per share for the current fiscal year.

Institutional Trading of Hologic

A number of hedge funds and other institutional investors have recently modified their holdings of HOLX. Brooklyn Investment Group grew its stake in shares of Hologic by 14.7% during the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock valued at $82,000 after buying an additional 145 shares during the last quarter. Smartleaf Asset Management LLC increased its position in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares in the last quarter. Trivant Custom Portfolio Group LLC raised its stake in Hologic by 2.1% in the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider's stock valued at $602,000 after buying an additional 169 shares during the last quarter. Beverly Hills Private Wealth LLC grew its holdings in shares of Hologic by 3.6% during the first quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider's stock valued at $320,000 after buying an additional 180 shares during the last quarter. Finally, UMB Bank n.a. raised its stake in shares of Hologic by 4.1% in the fourth quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider's stock worth $343,000 after purchasing an additional 188 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Company Profile

(Get Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Read More

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Should You Invest $1,000 in Hologic Right Now?

Before you consider Hologic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.

While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

This $13 Trillion Energy Breakthrough Will Make Millionaires
Magnificent 7 Stocks Shift Toward Stability and Selective Growth
4 Biotech Stocks on the Verge of Massive Breakthroughs

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines